←
Cédric Lebâcle2,577 posts
Cédric Lebâcle avatar

Cédric Lebâcle

@CLebacle

Improving patient outcomes & advancing the field. #BladderCancer #RoboticSurgery French Urologist at @Hopital_Bicetre @APHP

◷ Joined January 2014▧ 315 Photos and videos
Dr Rishabh Jain avatar
⟳ Cédric Lebâcle retweeted
Dr Rishabh Jain@DrRishabhOnco·26 Aug 2025

💥 MIBC is no longer surgery-first—oncology is rewriting the rulebook. 🩺 Surgery & Chemo (traditional backbone) Radical cystectomy ± peri-op cisplatin chemo remains standard, but morbidity & patient fitness limit its universal application. 🧬 Immunotherapy integration Neo/adjuvant ICB now proven: • CheckMate-274 → Nivolumab improved DFS & OS • AMBASSADOR → Pembrolizumab improved DFS • NIAGARA → Durvalumab peri-op improved DFS & OS 🧪 ctDNA as MRD tool • Detectable ctDNA predicts relapse post-cystectomy • IMvigor010, TOMBOLA, MODERN exploring ctDNA-guided escalation/de-escalation 🚦 → Personalised systemic therapy decisions on horizon. 🎯 ADCs + ICB combos • EV+pembro (EV-302) revolutionised metastatic setting • Now moving peri-op in VOLGA, KEYNOTE-905, KEYNOTE-B15 → Potential to boost cure rates in cisplatin-eligible & ineligible pts. 🛡️ Bladder-sparing strategies • TURBT + systemic therapy → durable CR in select pts (HCRN GU16-257, RETAIN) • Emerging risk-adapted, biomarker-driven pathways • Goal: preserve organ without compromising cure. ➡️ The next decade = convergence of powerful therapeutics + precise biomarkers + risk-adapted strategies. Not just longer survival-cure + quality of life together. 📖 JCO 2025 Review: ascopubs.org/doi/full/10.120… @ASCO @oncoalert @uro_today @theNCI #BladderCancer #Oncology #UroOnc #Immunotherapy #CancerResearch

Post attachment
Dra. María Natalia Gandur Quiroga avatar
⟳ Cédric Lebâcle retweeted
Dra. María Natalia Gandur Quiroga@nataliagandur·28 Nov 2024

💫🌟📢 The impact of radical cystectomy (RC) on sexual health & QoL🌟💫 Presenter: @PignotG | Moderator: @CLebacle #BLADDR24 @OncoAlert @mirrorsmed 🔍 Key Points: 🟠RC impacts sexual function significantly. Yet, 41.2% of urologists avoid discussing sexual outcomes with patients. 🟠Gender gap: Women are underserved in sexual health post-RC, highlighting the need for PROMS to guide improvements. 🟠Functional recovery: Sexual-sparing strategies lead to better sexual function & urinary continence, boosting QoL. 🟠Multimodal management (incl. sex therapy, physical treatments) enhances post-op outcomes for both genders. 🛠️ Call to Action: Incorporate sexual outcomes as a surgical endpoint & empower patients with comprehensive pre-op counseling! @UrsulaVogl @PGrivasMDPhD @achoud72 @ZilliThomas @fabioturco92 @yekeduz_emre @bavilima @niklas_kluemper @nachoduranm @schmidingerRCC @DrDabestani @PignotG @lisapic @DrYukselUrun @b_szabados #BladderCancer #UroOncology #QoL #PatientCare 🧑‍⚕️👩‍⚕️

Post attachmentPost attachmentPost attachmentPost attachment
Dra. María Natalia Gandur Quiroga avatar
⟳ Cédric Lebâcle retweeted
Dra. María Natalia Gandur Quiroga@nataliagandur·28 Nov 2024

💡 Highlights from #BLADDR24: Translating Data into Practice 🚨 Moderators: @CLebacle & Fred Witjes 🔥 Practical insights into intravesical instillation for bladder cancer: @OncoAlert @mirrorsmed Efficacy Tips: Limit voiding before therapy 🚫💧 & drink fluids after 💦. Toxicity Risks: Hygiene matters! Men should void sitting 👨‍⚕️🚻. Post-op timing matters for MMC—best on surgery day ⏰🔬. 2023 Guidelines: Continuous saline irrigation 🌊 recommended for chemo-ineligible. New tools like TAR-200 & GemRIS showing promise 🌟. @UrsulaVogl @PGrivasMDPhD @achoud72 @ZilliThomas @fabioturco92 @yekeduz_emre @bavilima @niklas_kluemper @nachoduranm @schmidingerRCC @DrDabestani @PignotG @lisapic @DrYukselUrun @b_szabados #OncoTwitter #UroOncology #BladderCancer

Post attachmentPost attachmentPost attachmentPost attachment
Petros Grivas avatar
⟳ Cédric Lebâcle retweeted
Petros Grivas@PGrivasMDPhD·27 Nov 2024

So fun to debate my friend & colleague @b_szabados on role of ctDNA in #bladdercancer citing data from TOMBOLA IMvigor011, etc. Great moderation by @DanieleRaggi83 @tompowles1 @Uromigos @AndreaNecchi @MattGalsky @JoshMeeks @achoud72 @KilianGust @OncoAlert @mirrorsmed #BLADDR24

💫🌟Debate: The Role of ctDNA in Adjuvant MIBC Management Moderator: Daniele Raggie SUPER PRESENTATION !!👏👏@PGrivasMDPhD, @b_szabados #BLADDR24 @OncoAlert @mirrorsmed 🔸️ctDNA+ post-RC detected in 52% of patients; 75% had recurrence <4 months. 🚨 🔸️Only 3% of ctDNA-negative patients developed metastases, promising for risk stratification. 🧬 🔸️IMvigor 010: ctDNA clearance correlated with improved DFS & OS! (HR 0.59) 📊 🔸️TOMBOLA trial highlights: ctDNA's predictive role needs validation—impact on NIAGARA awaited. 🔄 🟠🌟Future: Serial ctDNA testing to refine prognosis but requires addressing logistical hurdles. 📅 @UrsulaVogl @PGrivasMDPhD @achoud72 @ZilliThomas @fabioturco92 @yekeduz_emre @bavilima @niklas_kluemper @nachoduranm @schmidingerRCC @DrDabestani @PignotG @lisapic @DrYukselUrun @b_szabados #BLADDR24 #UroOncology #BladderCancer #ctDNA #PrecisionMedicine @OncoAlert @mirrorsmed

Post attachmentPost attachmentPost attachment
OncoAlert avatar
⟳ Cédric Lebâcle retweeted
OncoAlert@OncoAlert·27 Nov 2024

Day One of #BLADDR24 Presenter: Dr Cédric Lebâcle Debate: Are we ready to de-intensify treatment and surveillance in low-grade NMIBC? PRO and CON PRO: The debate on whether we are ready to de-intensify treatment and surveillance in low-grade non-muscle invasive bladder cancer (NMIBC) sees the "pro" side arguing that an adapted de-intensification strategy offers several benefits. These include minimizing the risks and side effects of interventions, reducing patient anxiety, and easing the treatment burden, all while ensuring safe and effective care. From a global perspective, this approach can help decrease unnecessary procedures in low-risk NMIBC patients without compromising cancer control, maintaining oncological outcomes while improving overall patient quality of life. @UrsulaVogl @PGrivasMDPhD @achoud72 @ZilliThomas @fabioturco92 @nataliagandur @yekeduz_emre @bavilima @niklas_kluemper @DrYukselUrun @mirrorsmed @bkonety @evacomperat @Achard_Verane @daandm @mdesantis234 @KilianGust @bkonety @CLebacle @LAUrology_NL @Renate_Pichler @DanieleRaggi83 @CelenaBergdahl @bm_deruiter Still time to Register: buff.ly/3Z4aEt3

Post attachmentPost attachmentPost attachmentPost attachment
Tom Powles avatar
⟳ Cédric Lebâcle retweeted
Tom Powles@tompowles1·15 Dec 2023

A big day for bladder ca patients @US_FDA. Massive team effort. Platinum based chemo superseded at last. EV/pembro will transform the lives of many pts with this difficult disease. Still lots to do but it’s a pretty good day and worth pausing for a moment. bit.ly/3GLntQn

Pignot Géraldine avatar
⟳ Cédric Lebâcle retweeted
Pignot Géraldine@PignotG·24 Nov 2023

#CFU2023 session TVIM : analyse PMSI sur > 5000 cystectomies en France : la cystectomie par voie robot-assistée permet de diminuer la durée moyenne de séjour (-2 j) et le coût moyen du séjour (-1600e). Encore un argument supplémentaire pour privilégier cette voie d'abord !

Post attachmentPost attachment
Cédric Lebâcle avatar
Cédric Lebâcle@CLebacle·18 Nov 2023

Le choix dépendra de ses intérêts personnels, de ses objectifs professionnels, et de la direction qu’il souhaite donner à sa carrière après OpenAI. @OpenAI

Cédric Lebâcle avatar
Cédric Lebâcle@CLebacle·18 Nov 2023

6.Rôle dans des Organisations à But Non Lucratif ou des Think Tanks : Avec son expérience, Altman pourrait apporter une contribution significative à des ONG, des think tanks ou des institutions travaillant sur des questions technologiques ou sociétales.

Cédric Lebâcle avatar
Cédric Lebâcle@CLebacle·18 Nov 2023

5.Recherche et Enseignement : Il pourrait également s’engager dans le milieu académique, contribuant à la recherche ou enseignant, partageant son expérience dans le domaine de l’IA et de l’entrepreneuriat.